Insmed Incorporated (NASDAQ:INSM) CEO William Lewis Sells 18,750 Shares of Stock

Insmed Incorporated (NASDAQ:INSM) CEO William Lewis sold 18,750 shares of the firm’s stock in a transaction dated Thursday, December 19th. The stock was sold at an average price of $69.91, for a total transaction of $1,310,812.50. Following the completion of the sale, the chief executive officer now directly owns 384,960 shares of the company’s stock, valued at approximately $26,912,553.60. This represents a 4.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Insmed Stock Performance

Shares of INSM opened at $70.44 on Friday. The company has a market cap of $12.60 billion, a price-to-earnings ratio of -12.69 and a beta of 1.10. The business’s fifty day simple moving average is $72.36 and its two-hundred day simple moving average is $71.77. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $80.53. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03.

Insmed (NASDAQ:INSM) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The company had revenue of $93.40 million during the quarter, compared to the consensus estimate of $93.36 million. During the same quarter in the previous year, the business earned ($1.10) earnings per share. Insmed’s revenue was up 18.1% compared to the same quarter last year. Research analysts anticipate that Insmed Incorporated will post -5.44 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. V Square Quantitative Management LLC purchased a new stake in shares of Insmed during the 3rd quarter valued at about $30,000. GAMMA Investing LLC grew its position in Insmed by 71.3% during the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 224 shares during the period. First Horizon Advisors Inc. raised its position in Insmed by 83.4% in the second quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company’s stock worth $42,000 after acquiring an additional 287 shares during the period. Exchange Traded Concepts LLC raised its position in Insmed by 522.5% in the third quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 627 shares during the period. Finally, Nisa Investment Advisors LLC grew its position in shares of Insmed by 8.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,778 shares of the biopharmaceutical company’s stock valued at $119,000 after acquiring an additional 135 shares during the period.

Analyst Ratings Changes

Several analysts have commented on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Insmed in a report on Monday, September 9th. Truist Financial restated a “buy” rating and set a $105.00 price target (up from $100.00) on shares of Insmed in a research report on Friday, November 1st. JPMorgan Chase & Co. increased their price objective on Insmed from $74.00 to $83.00 and gave the stock an “overweight” rating in a report on Friday, November 22nd. HC Wainwright restated a “buy” rating and set a $90.00 target price on shares of Insmed in a report on Friday, November 1st. Finally, Bank of America increased their price target on shares of Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a research note on Wednesday, October 9th. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $83.67.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.